Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 53

Cited In for PubMed (Select 21799510)

1.

Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Kandela I, Jin HY, Owen K; Reproducibility Project: Cancer Biology.

Elife. 2015 Jun 25;4:e07072. doi: 10.7554/eLife.07072.

2.

Profile of elotuzumab and its potential in the treatment of multiple myeloma.

Liu YC, Szmania S, van Rhee F.

Blood Lymphat Cancer. 2014 Jun;2014(4):15-27.

3.

Long-term disease control by pomalidomide-/dexamethasone-based therapy in a patient with advanced multiple myeloma: a case report and review of the literature.

Danhof S, Schreder M, Strifler S, Einsele H, Knop S.

Case Rep Oncol. 2015 Apr 17;8(1):189-95. doi: 10.1159/000381983. eCollection 2015 Jan-Apr.

4.

Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma.

Ocio EM, Dávila J, Caballero JC, Alonso S, de la Calle VG, García-Sanz R, Gazi L, Opio S, Jiménez M, San-Miguel JF, Mateos MV.

Haematologica. 2015 Jul;100(7):e289-91. doi: 10.3324/haematol.2015.124164. Epub 2015 Mar 20. No abstract available.

5.

The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.

Hanaizi Z, Flores B, Hemmings R, Camarero J, Sancho-Lopez A, Salmonson T, Gisselbrecht C, Laane E, Pignatti F.

Oncologist. 2015 Mar;20(3):329-34. doi: 10.1634/theoncologist.2014-0073. Epub 2015 Feb 11. Review.

6.

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.

Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK; Mayo Phase 2 Consortium.

Blood. 2015 Jan 15;125(3):443-8. doi: 10.1182/blood-2014-05-573741. Epub 2014 Nov 13.

PMID:
25395429
7.

Novel agents and new therapeutic approaches for treatment of multiple myeloma.

Ria R, Reale A, Vacca A.

World J Methodol. 2014 Jun 26;4(2):73-90. doi: 10.5662/wjm.v4.i2.73. eCollection 2014 Jun 26. Review.

8.

A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.

Chen S, Zhang Y, Zhou L, Leng Y, Lin H, Kmieciak M, Pei XY, Jones R, Orlowski RZ, Dai Y, Grant S.

Blood. 2014 Oct 23;124(17):2687-97. doi: 10.1182/blood-2014-03-564534. Epub 2014 Sep 10.

PMID:
25208888
9.

Lung postmortem autopsy revealing extramedullary involvement in multiple myeloma causing acute respiratory distress syndrome.

Ravinet A, Perbet S, Guièze R, Lemal R, Guérin R, Gayraud G, Aliane J, Tremblay A, Pascal J, Ledoux A, Chaleteix C, Dechelotte P, Bay JO, Bazin JE, Constantin JM.

Case Rep Hematol. 2014;2014:635237. doi: 10.1155/2014/635237. Epub 2014 Aug 6.

10.

Quantification of clonal circulating plasma cells in relapsed multiple myeloma.

Gonsalves WI, Morice WG, Rajkumar V, Gupta V, Timm MM, Dispenzieri A, Buadi FK, Lacy MQ, Singh PP, Kapoor P, Gertz MA, Kumar SK.

Br J Haematol. 2014 Nov;167(4):500-5. doi: 10.1111/bjh.13067. Epub 2014 Aug 12.

PMID:
25113422
11.

Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.

Gkotzamanidou M, Sfikakis PP, Kyrtopoulos SA, Bamia C, Dimopoulos MA, Souliotis VL.

Br J Cancer. 2014 Sep 23;111(7):1293-304. doi: 10.1038/bjc.2014.410. Epub 2014 Jul 22.

PMID:
25051404
12.
13.
14.

Potential role of daratumumab in the treatment of multiple myeloma.

Khagi Y, Mark TM.

Onco Targets Ther. 2014 Jun 18;7:1095-100. doi: 10.2147/OTT.S49480. eCollection 2014. Review.

15.

Salvage therapy of multiple myeloma: the new generation drugs.

Romano A, Conticello C, Cavalli M, Vetro C, Di Raimondo C, Di Martina V, Schinocca E, La Fauci A, Parrinello NL, Chiarenza A, Di Raimondo F.

Biomed Res Int. 2014;2014:456037. doi: 10.1155/2014/456037. Epub 2014 May 19. Review.

16.

Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis.

Papanikolaou X, Johnson S, Garg T, Tian E, Tytarenko R, Zhang Q, Stein C, Barlogie B, Epstein J, Heuck C.

Oncotarget. 2014 Jun 30;5(12):4118-28.

17.

Efficacy of lenalidomide in association with cyclophosphamide and dexamethasone in multiple myeloma patient with bilateral retro-orbital localisation.

Felici S, Villivà N, Balsamo G, Andriani A.

Ecancermedicalscience. 2013 Jul 10;7:331. doi: 10.3332/ecancer.2013.331. eCollection 2013.

18.

Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.

Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM.

Semin Cancer Biol. 2014 Aug;27:62-73. doi: 10.1016/j.semcancer.2014.03.001. Epub 2014 Mar 12. Review.

19.
20.

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.

Dimopoulos MA, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, Ludwig H, Morgan GJ, Davies FE, Sonneveld P, Schey SA, Zweegman S, Hansson M, Weisel K, Mateos MV, Facon T, Miguel JF.

Leukemia. 2014 Aug;28(8):1573-85. doi: 10.1038/leu.2014.60. Epub 2014 Feb 5. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk